Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  FIRST NORTH STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Biovica ISO 13485:2016 certificate renewal

share with twitter share with LinkedIn share with facebook
share via e-mail
10/25/2019 | 05:29am EST

Uppsala, Sweden, October 25, 2019. Biovica, active in cancer diagnostics, announced today that the company has renewed their ISO 13485:2016 certificate for three years following an extensive renewal audit with the company's accreditation body. The certificate covers the development, manufacturing and sale of DiviTum®. 

"The renewal of the certificate is important for Biovica as it proves that our quality management system fulfills the global quality requirements. The quality management system is a pre-requisite for market approval in both US and Europe and hence a must in order for Biovica to fulfill the vision of contributing to best treatment for cancer patients.", says Anders Rylander, CEO at Biovica.

Biovica has been ISO:13485 certified since 2010. ISO 13485 is an international standard that defines the requirements of the Quality Management System (QMS) for manufacturers of medical device.  The certificate has been renewed through a comprehensive renewal audit by Biovica's accreditation company. The certificate covers the development, manufacturing and sale of DiviTum.

For more information
Anders Rylander, CEO Biovica
phone: +46 (0)18 444 48 35
email: anders.rylander@biovica.com

Biovica - Best Treatment from Day One.

Biovica develops and commercializes blood-based biomarker assays to evaluate efficacy of cancer treatments. Biovica's assay DiviTum® measure cell proliferation by detecting a biomarker in the blood stream. The assay has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical trials. The first application for DiviTum is monitoring of treatment for patients with metastatic breast cancer. Biovica's vision is that all cancer patients will get an optimal treatment from day one. Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum is CE-marked and registered with the Swedish Medicines Agency. Biovica's shares are traded on the Nasdaq First North Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser, info@fnca.se, +46 8 528 00 399. For more information please visit: www.biovica.com.

https://news.cision.com/biovica-international-ab/r/biovica-iso-13485-2016-certificate-renewal,c2941427

https://mb.cision.com/Main/14910/2941427/1129926.pdf

https://news.cision.com/biovica-international-ab/i/iso-13485-2016-biovica,c2706564

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on BIOVICA INTERNATIONAL AB (
01/16BIOVICA INTERNATIONAL PUBL : Clinical Cancer Research publishes results supporti..
AQ
2019BIOVICA INTERNATIONAL PUBL : strengthens management team
AQ
2019Q2 INTERIM REPORT : Work with the FDA application progressing as planned
PU
2019Q2 INTERIM REPORT :  Work with the FDA application progressing as planned
AQ
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
PU
2019BIOVICA INTERNATIONAL PUBL : DiviTum - Strong prognostic marker in operable brea..
AQ
2019BIOVICA INTERNATIONAL PUBL : DiviTum validated as a dynamic biomarker in metasta..
AQ
2019BIOVICA INTERNATIONAL PUBL : strengthens with new R&D Director
AQ
2019BIOVICA ISO 13485 : 2016 certificate renewal
AQ
2019BIOVICA INTERNATIONAL PUBL : will present at the Biomarkers & Precision Medicine..
AQ
More news
Financials (SEK)
Sales 2020 5,00 M
EBIT 2020 -36,0 M
Net income 2020 -36,0 M
Finance 2020 12,0 M
Yield 2020 -
P/E ratio 2020 -11,9x
P/E ratio 2021 -83,4x
EV / Sales2020 84,1x
EV / Sales2021 11,7x
Capitalization 433 M
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price
Last Close Price 18,35  
Spread / Highest target -
Spread / Average Target -
Spread / Lowest Target -
EPS Revisions
Managers
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving Chief Financial Officer
Karin Mattsson Director-Research & Development
Sector and Competitors